English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background Adenosine has traditionally been utilized for coronary hyperemia during myocardial perfusion assessment in adults, however regadenoson has recently become more popular [1]. With improved survival of congenital heart disease (CHD), and increased diagnosis of acquired heart disease (AHD), there’s an increasing need for assessment of myocardial perfusion in pediatrics [2]. Only dipyridamole and adenosine have reportedly been utilized as hyperemia stressors in CHD patients. As a selective A2A agonist, regadenoson has a more favorable side-effect profile and less stimulation of receptors associated with bronchospasm, and decreased chronotropy [1]. It is administered as an intravenous (IV) bolus and thus only a single IV is required. Peak onset is at 60-90 seconds, with hyperemia lasting up to 6 minutes allowing additional wall motion assessment [3].

Regadenoson as a pharmacologic stressor in cardiac magnetic resonance imaging in congenital and acquired pediatric heart disease: initial experience